Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).

Kawaguchi Y, Hayashi K, Shimokawa M, Otsuka T, Nakazawa J, Shimokawa H, Shinohara Y, Koga F, Oza N, Oda H, Takeshita S, Arima S, Arita S, Nishikawa K, Otsu S, Taguchi H, Jikuya K, Sakai T, Ueda Y, Sakae T, Araki N, Sawase H, Ide Y, Kawahira M, Nio K, Shirakawa T, Mizuta T, Mitsugi K

Open source

DOI: 10.1177/17588359261442386
Published: 2026
Container: Therapeutic advances in medical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/17588359261442386,
  title = {Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).},
  author = {Kawaguchi Y and Hayashi K and Shimokawa M and Otsuka T and Nakazawa J and Shimokawa H and Shinohara Y and Koga F and Oza N and Oda H and Takeshita S and Arima S and Arita S and Nishikawa K and Otsu S and Taguchi H and Jikuya K and Sakai T and Ueda Y and Sakae T and Araki N and Sawase H and Ide Y and Kawahira M and Nio K and Shirakawa T and Mizuta T and Mitsugi K},
  year = {2026},
  journal = {Therapeutic advances in medical oncology},
  doi = {10.1177/17588359261442386},
  url = {https://doi.org/10.1177/17588359261442386}
}

RIS

TY  - JOUR
TI  - Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).
AU  - Kawaguchi Y
AU  - Hayashi K
AU  - Shimokawa M
AU  - Otsuka T
AU  - Nakazawa J
AU  - Shimokawa H
AU  - Shinohara Y
AU  - Koga F
AU  - Oza N
AU  - Oda H
AU  - Takeshita S
AU  - Arima S
AU  - Arita S
AU  - Nishikawa K
AU  - Otsu S
AU  - Taguchi H
AU  - Jikuya K
AU  - Sakai T
AU  - Ueda Y
AU  - Sakae T
AU  - Araki N
AU  - Sawase H
AU  - Ide Y
AU  - Kawahira M
AU  - Nio K
AU  - Shirakawa T
AU  - Mizuta T
AU  - Mitsugi K
PY  - 2026
JO  - Therapeutic advances in medical oncology
DO  - 10.1177/17588359261442386
UR  - https://doi.org/10.1177/17588359261442386
ER  -

APA

Y, K., K, H., M, S., T, O., J, N., H, S., Y, S., F, K., N, O., H, O., S, T., S, A., S, A., K, N., S, O., H, T., K, J., T, S., Y, U., T, S., N, A., H, S., Y, I., M, K., K, N., T, S., T, M., & K, M. (2026). Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359261442386

Source records

pubmed · retrieved 2026-09-27T01:29:37.343Z
europe-pmc · retrieved 2026-09-27T01:29:37.355Z
doaj · retrieved 2026-09-27T01:29:37.356Z